CFH and thrombotic thrombocytopenic purpura: Different nosological entities as currently defined [25] may overlap, and comprehensive functional and genetic studies are needed to avoid diagnostic pitfalls, such as the presence of complement regulator mutations and/or anti-CFH antibodies [10,12,26], particularly in patients presenting with a complicated or protracted course of TTP.